BioLineRx Ltd.
BLRXBioLineRx Ltd. in brief
BioLineRx Ltd. is a listed company in the Biotechnology industry, based in Israel. It was founded in 2003. Its market value was $12 M on 1 August 2026, which makes it the 25,529th largest listed company in the world and the 269th largest in Israel on this site. In the year to December 2025 it had sales of $1 M and a net loss of $2 M. Philip A. Serlin is its chief executive. By market, the largest shares of its 2025 sales came from U.S. (100%). Its shares trade under the symbol BLRX (Nasdaq).
Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.
About BioLineRx Ltd.
BioLineRx Ltd. (Hebrew: ביוליין אר אקס), or BioLine, is a publicly traded drug development company. Headquartered in Israel, its shares are traded on the NASDAQ Capital Market and on the Tel Aviv Stock Exchange.
From Wikipedia: read the full article · text available under CC BY-SA 4.0
BioLineRx Ltd. timeline
- 2003
- 🏁· approximateFounded
- 2010
- •· approximateFirst filing with the US SECThe company's first electronic filing in SEC EDGAR.
Events of BioLineRx Ltd. from Wikidata and SEC EDGAR. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
Market cap history
World rank over time
Rank in Israel: #309 (Jan 2020) · #272 (Jan 2021) · #298 (Jan 2022) · #332 (Dec 2022) · #262 (Jul 2023) · #263 (Jan 2024) · #51 (Mar 2026) · #269 (Aug 2026)
Key ratios
- P/E ratio (TTM)
- n/m (loss)
- Price / sales (TTM)
- 10.2×
- Price / book
- 0.7×
- Free cash flow yield
- -67.1%
- Net margin (TTM)
- -172.0%
- Operating margin
- -872.0%
- Return on equity
- -11.2%
- Liabilities / assets
- 42.9%
- Revenue growth
- -95.9%
- R&D / revenue
- 685.6%
Financial history
| Fiscal year ending | Revenue | Growth | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $1M | -95.9% | $-10M | $-2M | -172.0% |
| Dec 2024 | $29M | +502.9% | $-20M | $-9M | -31.9% |
| Dec 2023 | $5M | — | $-50M | $-61M | -1262.7% |
| Dec 2022 | — | — | $-29M | $-25M | — |
| Dec 2021 | — | — | $-25M | $-27M | — |
| Dec 2020 | — | — | $-23M | $-30M | — |
| Dec 2019 | — | — | $-28M | $-25M | — |
| Dec 2018 | — | — | $-26M | $-23M | — |
Cash flow, debt and per share
| Fiscal year ending | Operating cash flow | Capital spending | Free cash flow | EPS (diluted) | Dividend / share |
|---|---|---|---|---|---|
| Dec 2025 | $-8M | $0M | $-8M | $0.00 | — |
| Dec 2024 | $-44M | $0M | $-44M | $-0.01 | — |
| Dec 2023 | $-23M | $0M | $-23M | $-0.06 | — |
| Dec 2022 | $-26M | $0M | $-26M | $-0.03 | — |
| Dec 2021 | $-24M | $0M | $-24M | $-0.04 | — |
| Dec 2020 | $-23M | $0M | $-23M | $-0.12 | — |
| Dec 2019 | $-23M | $0M | $-23M | — | — |
| Dec 2018 | $-24M | $0M | $-24M | — | — |
SEC filings
- Oct 23, 20266-KReport of foreign issuer
- Sep 25, 2026F-1IPO registration (foreign issuer)
- Sep 24, 20266-KReport of foreign issuer
- Sep 10, 20266-KReport of foreign issuer
- Aug 31, 20266-KReport of foreign issuer
- Aug 31, 20266-KReport of foreign issuer
- Aug 28, 20266-KReport of foreign issuer
- Aug 18, 20266-KReport of foreign issuer
- Jul 8, 20266-KReport of foreign issuer
- May 27, 20266-KReport of foreign issuer
- May 22, 20266-KReport of foreign issuer
- May 19, 20266-KReport of foreign issuer
Official filings of BioLineRx Ltd. with the US Securities and Exchange Commission.
Annual results
- Revenue
- $1 M
- Operating income
- $-10 M
- Net income
- $-2 M
For year ending December-2025 · source: SEC filing
Balance sheet
- Total assets
- $41 M
- Total liabilities
- $18 M
- Total equity
- $18 M
As of December-2025
Top 17 institutional investors in BioLineRx Ltd.#
| # | Institution | Shares held | Change (shares) | Value | Filed |
|---|---|---|---|---|---|
| 1 | Armistice Capital, LLC | 473,000 | New | $1 M | Nov 16, 2026 |
| 2 | Citadel Advisors LLC | 30,087 | +15,291 (+103.35%) | $0 M | Nov 16, 2026 |
| 3 | Susquehanna International Group, LLP | 20,551 | -10,360 (-33.52%) | $0 M | Nov 16, 2026 |
| 4 | Stifel Financial Corp | 20,041 | New | $0 M | Nov 12, 2026 |
| 5 | Renaissance Technologies LLC | 18,900 | +3,488 (+22.63%) | $0 M | Nov 12, 2026 |
| 6 | Rhumbline Advisers | 2,478 | 0 (0.00%) | $0 M | Nov 10, 2026 |
| 7 | Wells Fargo & Company/mn | 1,750 | -250 (-12.50%) | $0 M | Nov 16, 2026 |
| 8 | Nemes Rush Group LLC | 250 | 0 (0.00%) | $0 M | Nov 4, 2026 |
| 9 | Tower Research Capital LLC (TRC) | 181 | New | $0 M | Nov 16, 2026 |
| 10 | UBS Group AG | 157 | +56 (+55.45%) | $0 M | Nov 10, 2026 |
| 11 | NewEdge Advisors, LLC | 82 | 0 (0.00%) | $0 M | Nov 13, 2026 |
| 12 | Osaic Holdings, Inc. | 51 | +25 (+96.15%) | $0 M | Nov 12, 2026 |
| 13 | BFC Planning, Inc. | 28 | 0 (0.00%) | $0 M | Nov 13, 2026 |
| 14 | SBI Securities Co., Ltd. | 10 | 0 (0.00%) | $0 M | Oct 22, 2026 |
| 15 | Danske Bank A/s | 2 | 0 (0.00%) | $0 M | Nov 9, 2026 |
| 16 | Caitong International Asset Management Co., Ltd | 2 | New | $0 M | Oct 29, 2026 |
| 17 | Banque Cantonale Vaudoise | 1 | 0 (0.00%) | $0 M | Nov 12, 2026 |
Markets and events: BioLineRx Ltd.#
Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.
Trading halts
- 2025-01-30 00:50 UTC, code T3, resumed 14:00 UTC
Fails to deliver
- : 242 shares at $2.07
- : 399 shares at $2.13
- : 916 shares at $2.01
- : 1,862 shares at $2.34
- : 140 shares at $2.28
Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables
BioLineRx Ltd. scorecard#
Passes 2 of the 11 checks that could be worked out: strongest in financial health (1 of 4), weakest in profitability (0 of 4). Fiscal year 2025; market cap of Aug 1, 2026.
Valuationnot known
- –P/E below its peers' medianThe market cap dates from 2026-08-01, more than 60 days ago.
- –Price to book below its peers' medianThe market cap dates from 2026-08-01, more than 60 days ago.
- –Price to sales below its peers' medianThe market cap dates from 2026-08-01, more than 60 days ago.
- –Free cash flow yield above 5%The market cap dates from 2026-08-01, more than 60 days ago.
- –Earnings yield above the 10-year Treasury yieldThe market cap dates from 2026-08-01, more than 60 days ago.
- –The price assumes slower growth than the last three years'The market cap dates from 2026-08-01, more than 60 days ago.
Growth1 of 2
- –Revenue grew in the newest yearRevenue of the year before is not on file.
- –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
- –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
- ✗Earnings per share grew in the newest year0.00 vs -0.01Diluted EPS 0.00 in fiscal 2025 against -0.01 the year before (report's currency).
- ✓Net income higher than five years earlier-$2 M-$2 M in fiscal 2025 against -$30 M in 2020.
- –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
Profitability0 of 4
- ✗Profitable in the newest year-$2 MNet income -$2 M in fiscal 2025.
- ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
- ✗Operating margin above its peers' median-872.0%-872.0% against Biotechnology's median of -60.5% (243 companies).
- ✗Return on equity above 15%-12.8%-12.8% in fiscal 2025.
- –Return on invested capital above 10%No return on invested capital on file.
- –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
Financial health1 of 4
- ✓Short-term assets cover short-term liabilities1.9×Current ratio 1.95 at the end of fiscal 2025.
- –Debt below equityDebt or equity is not on file (or equity is negative).
- –Net debt below three years of EBITDANet debt to EBITDA is not on file.
- ✗Operating income covers interest five times-8.0×Operating income -8.0 times interest in fiscal 2025.
- ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
- ✗Altman Z-score outside the distress zone-13.78Z-score -13.78 (distress zone) for fiscal 2025.
Shareholder returns0 of 1
- –Pays a dividendDividends are not on file.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- ✗Share count up no more than 2% in a year105.8%Diluted shares up 105.8% in fiscal 2025.
- –Dividends and buybacks above 3% of the market valueThe market cap dates from 2026-08-01, more than 60 days ago.
- –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.
Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 20, 2026 and the market cap (too old for the valuation checks, which need one at most 60 days old). A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
Financial analysis, 2025#
Worked out from BioLineRx Ltd.'s statements, beside the median of Biotechnology.
| Ratio | Trend | 2025 | Median of peers |
|---|---|---|---|
| Operating margin | -872.0% | -60.5% | |
| Net margin | -172.0% | -68.9% | |
| Return on equity | -12.8% | -61.0% | |
| Free cash flow margin | -685.6% | -61.5% |
3of 8on the Piotroski tests of financial strength
- Net loss of $2 million, the 11th loss-making year in a row.
- Free cash flow was negative: -$8 million.
- The share count rose 105.8% in the year.
- Operating income covers the interest bill only -8.0 times.
BioLineRx Ltd.: financial statements#
Income statement, balance sheet and cash-flow statement as reported, newest period first.
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | FY 2025to Dec 31, 2025 | FY 2024to Dec 31, 2024 | FY 2023to Dec 31, 2023 | FY 2022to Dec 31, 2022 | FY 2021to Dec 31, 2021 | FY 2020to Dec 31, 2020 | FY 2019to Dec 31, 2019 | FY 2018to Dec 31, 2018 | FY 2017to Dec 31, 2017 | FY 2016to Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||||
| Revenue | 1.2−95.9%100% | 29+503%100% | 4.8—100% | 0—— | 0—— | — | — | — | — | — | |
| Cost of revenue | 0.2−97.5%19.5% | 9.3+151%32.0% | 3.7—76.9% | 0—— | 0—— | — | — | — | — | — | |
| Gross profit | 1.0−95.2%80.5% | 20+1676%68.0% | 1.1—23.1% | 0—— | 0—— | — | — | — | — | — | |
| Research and development | 8.1−11.5%686% | 9.1−26.9%31.6% | 13−29.0%261% | 18−9.4%— | 19+7.1%— | 18−22.5%— | 23+18.3%— | 20+1.5%— | 20+74.6%— | 11—— | |
| Selling, general and administrative | 3.1−50.3%266% | 6.3+0.2%21.8% | 6.3+24.6%131% | 5.1+17.6%— | 4.3+10.1%— | 3.9+2.6%— | 3.8−14.0%— | 4.4+9.9%— | 4.0+1.3%— | 4.0—— | |
| Selling and marketing | 0−100%0.0% | 24−6.6%81.6% | 25+291%526% | 6.5+544%— | 1.0+19.4%— | 0.8−2.0%— | 0.9−37.1%— | 1.4−19.6%— | 1.7+25.2%— | 1.4—— | |
| Operating income | −10—−872% | −20—−70.5% | −50—−1035% | −29—— | −25—— | −23—— | −28—— | −26—— | −25—— | −17—— | |
| Interest and finance income | 1.1−38.2%95.3% | 1.8−9.3%6.3% | 2.0+189%41.8% | 0.7+151%— | 0.3r0.6+17.4%— | 0.2−69.6%— | 0.8+8.1%— | 0.7−38.5%— | 1.2+144%— | 0.5—— | |
| Interest expense and finance costs | 1.3−86.0%108% | 9.1+320%31.5% | 2.2+0.5%45.2% | 2.2+115%— | 1.0−38.2%— | 1.6−28.5%— | 2.3+381%— | 0.5+2152%— | 0.0−4.5%— | 0.0—— | |
| Income tax | 0—0.0% | 0—0.0% | 0—0.0% | 0—— | 0—— | 0—— | 0—— | — | — | — | |
| Net income including minority interests | −2.0—−172% | −9.2—−31.9% | −61—−1263% | −25—— | −27—— | −30—— | −25—— | −23—— | −24—— | −16—— | |
| Minority interests' share of net income | 6.0—508% | — | — | — | — | — | — | — | — | — | |
| Earnings per share, basic | 0.00—— | -0.01—— | -0.06—— | -0.03—— | -0.04—— | -0.12—— | — | — | — | — | |
| Earnings per share, diluted | 0.00—— | -0.01—— | -0.06—— | -0.03—— | -0.04—— | -0.12—— | — | — | — | — | |
| Shares, weighted average (basic) | 2,465+106%— | 1,198+24.4%— | 963+24.5%— | 774+16.7%— | 663+162%— | 253+72.7%— | 146+34.8%— | 109+20.7%— | 90+60.2%— | 56—— | |
| Shares, weighted average (diluted) | 2,465+106%— | 1,198+24.4%— | 963—— | — | — | — | — | — | — | — | |
| Balance sheet | |||||||||||
| Cash and cash equivalents | 3.3−68.9%7.9% | 10+145%26.8% | 4.3−59.8%6.7% | 11−18.5%13.9% | 13−22.8%16.0% | 17+218%35.6% | 5.3+55.6%9.9% | 3.4−33.4%6.1% | 5.1+107%8.4% | 2.5—6.3% | |
| Inventory | 2.1−31.7%5.3% | 3.1+61.0%8.1% | 2.0—3.1% | 0—0.0% | — | — | — | — | — | — | |
| Current assets | 24−12.6%57.9% | 27−42.6%69.7% | 47−9.3%73.8% | 52−9.4%68.1% | 57+151%70.5% | 23−18.9%48.4% | 28−11.8%52.7% | 32−36.5%56.9% | 50+39.5%82.6% | 36—92.7% | |
| Property, plant and equipment | 0.2−58.5%0.4% | 0.4−18.4%1.0% | 0.5−34.8%0.7% | 0.7−23.7%1.0% | 1.0−29.0%1.2% | 1.3−26.2%2.8% | 1.8−18.5%3.4% | 2.2−11.1%4.0% | 2.5−3.8%4.1% | 2.6—6.7% | |
| Right-of-use (leased) assets | 0.7−28.0%1.7% | 1.0−31.7%2.5% | 1.4−20.1%2.2% | 1.8+33.1%2.3% | 1.3−1.8%1.6% | 1.4−17.9%2.9% | 1.7—3.1% | — | — | — | |
| Other intangible assets | 16+56.6%40.0% | 10−29.7%26.9% | 15−32.1%23.2% | 22+0.8%28.7% | 22−0.0%26.7% | 22−0.8%45.9% | 22−0.4%40.9% | 22+213%39.1% | 7.0+3780%11.5% | 0.2—0.5% | |
| Non-current assets | 17+45.9%42.1% | 12−29.5%30.3% | 17−31.3%26.2% | 24+1.7%31.9% | 24−1.7%29.5% | 24−3.7%51.6% | 25+4.5%47.3% | 24+129%43.1% | 11+273%17.4% | 2.8—7.3% | |
| Total assets | 41+5.1%100% | 39−39.1%100% | 64−16.3%100% | 76−6.2%100% | 81+72.1%100% | 47−11.7%100% | 54−4.7%100% | 56−7.8%100% | 61+56.6%100% | 39—100% | |
| Debt due within a year | 4.50.0%10.9% | 4.5+42.4%11.5% | 3.1+104%4.9% | 1.5−44.1%2.0% | 2.8−10.8%3.4% | 3.1+14.9%6.5% | 2.7+201%5.0% | 0.9+862%1.6% | 0.10.0%0.2% | 0.1—0.2% | |
| Current liabilities | 12−21.3%29.6% | 15−64.0%39.6% | 43r31+301%66.9% | 11+9.9%14.0% | 9.7−8.7%11.9% | 11−11.1%22.5% | 12+77.3%22.3% | 6.8+0.4%12.0% | 6.7+83.6%11.0% | 3.7—9.4% | |
| Lease liabilities (non-current) | 1.0−9.6%2.4% | 1.1−16.2%2.8% | 1.3−25.4%2.0% | 1.7+0.2%2.3% | 1.7+3.9%2.1% | 1.7−5.7%3.5% | 1.8—3.3% | — | — | — | |
| Non-current liabilities | 5.4−45.8%13.3% | 10+26.8%25.8% | 7.9r20−46.7%12.4% | 15+315%19.5% | 3.6−75.5%4.4% | 15+77.9%30.9% | 8.2+0.7%15.3% | 8.2+499%14.5% | 1.4+443%2.2% | 0.3—0.6% | |
| Total liabilities | 18−31.0%42.9% | 25−49.8%65.4% | 51+98.5%79.3% | 26+92.0%33.4% | 13−47.3%16.3% | 25+25.1%53.4% | 20+35.4%37.7% | 15+84.5%26.5% | 8.1+107%13.3% | 3.9—10.0% | |
| Retained earnings | −401—−980% | −400—−1028% | −391—−611% | −330—−432% | −305—−375% | −278—−588% | −248—−463% | −223—−396% | −200—−327% | −175—−450% | |
| Shareholders' equity | 18+35.2%44.5% | 13—34.6% | — | — | — | — | — | — | — | — | |
| Minority interests | 5.1—12.6% | 0—0.0% | — | — | — | — | — | — | — | — | |
| Total equity | 23+73.4%57.1% | 13+1.8%34.6% | 13−74.0%20.7% | 51−25.3%66.6% | 68+209%83.7% | 22−34.0%46.6% | 33−19.2%62.3% | 41−21.9%73.5% | 53+51.0%86.7% | 35—90.0% | |
| Total liabilities and equity | 41+5.1%100% | 39−39.1%100% | 64−16.3%100% | 76−6.2%100% | 81+72.1%100% | 47−11.7%100% | 54−4.7%100% | 56−7.8%100% | 61+56.6%100% | 39—100% | |
| Cash-flow statement | |||||||||||
| Depreciation and amortization | 0.5−87.1%44.3% | 4.1+194%14.0% | 1.4+112%28.8% | 0.7−7.0%— | 0.7−24.7%— | 0.9−0.6%— | 0.9+72.5%— | 0.5+13.3%— | 0.5−0.2%— | 0.5—— | |
| Share-based compensation | 0.4−65.1%33.6% | 1.1−51.1%3.9% | 2.3+3.4%48.4% | 2.2+50.2%— | 1.5+17.5%— | 1.3−27.7%— | 1.8−30.4%— | 2.5+67.5%— | 1.5+40.3%— | 1.1—— | |
| Cash from operating activities | −8.1—−684% | −44—−152% | −23—−471% | −26—— | −24—— | −23—— | −23—— | −24—— | −21—— | −15—— | |
| Capital expenditure | −0.0—−2.1% | −0.1—−0.2% | −0.1—−2.4% | −0.1—— | −0.1—— | 0—— | −0.1—— | −0.2—— | −0.3—— | −0.1—— | |
| Intangible assets bought | −0.0—−0.2% | −0.0—−0.0% | −0.2—−3.8% | −0.2—— | 0—— | 0—— | −0.0—— | −10—— | −3.9—— | −0.0—— | |
| Cash from investing activities | −8.5−129%−724% | 29+1934%101% | 1.4−64.0%30.1% | 4.0—— | −38−329%— | 17+217%— | 5.3−45.0%— | 9.6—— | −16−271%— | 9.3—— | |
| Debt issued | 9.1−67.5%770% | 28—96.6% | — | 18—— | — | — | — | — | — | — | |
| Debt repaid | −5.6—−472% | −23—−78.8% | −1.5r−1.5—−32.1% | −3.2r−2.8—— | −3.8r−3.4—— | −3.1—— | −0.9—— | −0.4r−0.3—— | −0.1—— | — | |
| Shares issued | 14−15.1%1177% | 16+16.1%56.5% | 14−1.9%294% | 14−71.5%— | 50+162%— | 19r21−5.2%— | 20+430%— | 3.8−90.1%— | 39+1676%— | 2.2—— | |
| Cash from financing activities | 8.9−57.0%753% | 21+37.2%71.4% | 15−26.3%314% | 20−64.6%— | 58+223%— | 18−6.9%— | 19+46.6%— | 13−66.1%— | 39+1751%— | 2.1—— | |
| Exchange-rate effect on cash | 0.5+2395%46.5% | 0.0—0.1% | −0.2—−4.7% | −0.6−393%— | 0.2+0.5%— | 0.2+90.7%— | 0.1—— | −0.2−138%— | 0.4+753%— | 0.1—— | |
| Change in cash | −7.7−226%−656% | 6.2—21.3% | −6.1—−127% | −1.8—— | −4.0−136%— | 11+535%— | 1.8—— | −1.5−170%— | 2.2—— | −3.1—— | |
| Report | 20-F | 20-F | 20-F | 20-F | 20-F/A | 20-F | 20-F | 20-F | 20-F | 20-F | |
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.
Source: SEC EDGAR filings (XBRL) · as of Dec 31, 2025. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative
What BioLineRx Ltd. sells: revenue by product line, fiscal 2025#
As the company reports it, in US dollars, with each line's share of total revenue and the change on fiscal 2024. Lines can overlap (a total and its parts), so they are not added up.
Countries and regions
- 🇺🇸 U.S.$1 M100%-92%
Source: SEC annual report (XBRL data) · as of Dec 31, 2025
Where BioLineRx Ltd. operates: 3 countries#
Countries where the company has its headquarters, an office, subsidiaries, a branch or reported revenue.
| Country | Presence | Revenue there |
|---|---|---|
| 🇮🇱 Israel | Headquarters1 office | — |
| 🇵🇸 Palestine | 1 office | — |
| 🇺🇸 USA | $1 M100% |
Source: GLEIF legal-entity register, SEC Exhibit 21 and annual reports, office addresses on file. A country without subsidiaries or offices on record is not listed even if the company sells there. How presence is decided
Acquisitions and funding#
Private share sales · funding history
Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.
How BioLineRx Ltd. compares in Biotechnology
- Market cap$12 M · higher than 12% of 726
- Revenue$1 M · higher than 26% of 647
- Net margin-172.0% · higher than 31% of 408
- Revenue growth-95.9% · higher than 2% of 438
- Price / sales10.2× · lower than 43% of 339
- Price / book0.7× · lower than 87% of 534
- FCF yield-67.1% · higher than 18% of 449
Peer comparison · Biotechnology
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| BioLineRx Ltd.🇮🇱 | $12 M | — | -172.0% | -95.9% |
| Novo Nordisk A/S🇩🇰 | $203.2 B | 13.1× | 33.1% | +10.8% |
| Vertex Pharmaceuticals Incorporated🇺🇸 | $134.3 B | 33.8× | 30.7% | +8.9% |
| Moderna, Inc.🇺🇸 | $90.1 B | — | -110.5% | -39.9% |
| Regeneron Pharmaceuticals, Inc.🇺🇸 | $84.1 B | 17.5× | 28.5% | +1.0% |
| Argenx SE🇳🇱 | $52.8 B | 40.9× | 31.1% | +89.9% |
| CSL Limited🇦🇺 | $51.6 B | — | -16.4% | — |
| Samsung Biologics Co., Ltd.🇰🇷 | $51.5 B | 40.5× | 39.2% | — |
| UCB SA🇧🇪 | $48.6 B | 26.3× | 20.1% | +31.1% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
- Regenxbio Inc.$513 M
- Pharmicell Co., Ltd.$514 M
- Oneness Biotech Co., Ltd.$520 M
- Pulike Biological Engineering, Inc.$524 M
- Contineum Therapeutics, Inc.$534 M
- Entera Bio Ltd.$543 M
Sources and freshness
- Market cap:
- Aug 1, 2026
- Annual results:
- For year ending December-2025
- Balance sheet:
- As of December-2025
- Profile updated:
- Nov 21, 2026
Figures from Market data, SEC filing, Wikidata, value.today research, Wikipedia; financial statements from SEC filings.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at BioLineRx Ltd.? Verify and update this profile — free
Show BioLineRx Ltd.'s ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.